Opinion

Video

Treatments for Patients With Newly Diagnosed Metastatic Cervical Cancer

Author(s):

Claire Friedman, MD,Emily Davan, RN

Clinical insights on treatment options for patients with newly diagnosed metastatic cervical cancer, with a focus on immunotherapy and the KEYNOTE-826 trial.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of Dr. Salani.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Related Content
Advocacy text.
June 25th 2025

When Cancer Advocacy Becomes a Lifeline

Morgan Newman
Cancer survivor Morgan Newman shares how self-advocacy helped her overcome barriers to care and find the support she needed after treatment.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Biomarker testing is vital for all patients with lung cancer: © stock.adobe.com.
May 8th 2025

Biomarker Testing Remains Crucial for Young Patients With Lung Cancer

Spencer Feldman
Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations.
Kate Weissman, a gynecologic cancer survivor
November 30th 2023

Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer

Alex Biese
Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks: © stock.adobe.com
April 18th 2025

Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks

Alex Biese
Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.